小梁切除术患者终生视力结局
共纳入156例患者(196眼),术后预期寿命7.5年,多数眼在余生中维持视功能,严重视力丧失者中仅四分之一归因于青光眼进展。
要点
- 小梁切除术能减缓或阻止多数眼青光眼进展,维持余生视功能。
- 临终严重视力丧失者中仅约四分之一由青光眼进展所致。
- 44%患者临终时仍需使用青光眼降眼压滴眼液。
核心结论
- 小梁切除术在多数眼中成功减缓或阻止青光眼进一步进展,从而在余生维持视功能。
- 临终严重视力丧失者中仅四分之一由青光眼进展所致。
研究设计与样本
- 659例中160例死亡(24.3%),排除4例数据不足,最终分析156例患者(196眼)。
主要发现
- 男女比例3:2,86%为白人,首眼手术平均年龄76.5岁(SD 9.0)。
- 小梁切除术后预期寿命7.5年(范围0.1-17.2年)。
- 视力平均变化为LogMAR 0.32(SD 0.59),视野平均偏差中位进展-0.44 dB/年(从-5.98到3.9,限于随访至少1年的眼)。
- 78眼(40%)发生严重视力丧失(LogMAR视力丧失≥10个字母),其中18眼(9%)由青光眼所致。
- 69例患者(44%)临终时仍需青光眼滴眼液。
临床怎么用
- 小梁切除术可长期维持多数患者视功能,临终严重视力丧失多非青光眼进展所致。
局限性
- 仅纳入死亡患者,可能存在选择偏倚。
- 部分眼随访不足一年,视野进展数据受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most important outcome for patients undergoing trabeculectomy is to maintain the quality of life in their remaining years. This study quantifies end of life vision in terms of visual acuity (VA) and visual field status. METHODS: A prospective service evaluation of patients undergoing trabeculectomy (from 2000 to 2012) who died prior to the study evaluation point (November 2018). Demographic data including socioeconomic status were collected and change in clinical measurement for the cohort between time of surgery and death was measured. RESULTS: 160 of 659 patients had died (24.3%), 4 were excluded due to insufficient data, leaving 156 patients (196 eyes) for evaluation. Male-to-female ratio was 3:2, 86% of patients were Caucasian. Mean age at surgery on first eye was 76.5 years (SD 9.0). Life expectancy post-trabeculectomy was 7.5 years (0.1-17.2). Mean change in VA was logarithm of the mean angle of resolution (LogMAR) 0.32 (SD 0.59) and visual field mean deviation progressed at a median of -0.44 dB/year (from -5.98 to 3.9) for eyes with at least a year of follow-up. Severe vision loss (loss of ≥10 letters on LogMAR) occurred in 78 eyes (40%) of which 18 (9%) were due to glaucoma, 69 patients (44%) required glaucoma drops at end of life. CONCLUSION: Trabeculectomy is successful in slowing or preventing further glaucoma progression and thus maintaining visual function in the majority of eyes for the remainder of life. For those with severe vision loss at the end of life, only one in four was due to further progression of their glaucoma.
引用
- Chen R, King AJ. Lifetime visual outcomes of patients undergoing trabeculectomy. Br J Ophthalmol. 2020. PMID: 32950960. doi:10.1136/bjophthalmol-2020-317004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。